■ Introduction
Parkinson disease (PD) is a neurologic disorder caused by neurodegeneration of the nigrostriatal dopaminergic pathway. 1 Lower urinary tract symptoms (LUTS) occur in 7% to 70% of patients during the course of the disease that negatively influence health-related quality of life medication for at least 3 months prior to enrollment and if the dosage did not change over the duration of their participation in the study. All patients were being treated for PD. If participants reported any worsening of PD symptoms during data collection, they were evaluated again by the neurologist using the UPDRS. Participants found to have changes in their UPDRS scores were withdrawn from the study.
Study Procedures
After eligible patients were identifi ed on the basis of inclusion and exclusion criteria discussed earlier, study procedures were explained and written consent was obtained. Data collection before and after the intervention was performed by a physiotherapist, except for the urodynamic study, which was performed by a physician. Both physiotherapist and physician were blinded to participant group assignment. Patients were taught how to complete a 3-day bladder diary that registered times of diurnal and nocturnal micturition, episodes of urgency, and urinary incontinence. Study participants then completed the OAB-V8 and ICIQ-SF.
Urodynamic testing was completed during baseline evaluation; International Continence Society recommendations for good urodynamic practices were followed. 19 Filling cystometry and voiding pressure fl ow studies were performed with the patients in the standing position using a 6F catheter used to measure intravesical pressure and an 8F catheter for intravesical infusion. Abdominal pressure was measured with a rectal balloon fi lled with approximately 5 ml of water. The bladder was fi lled with saline solution at room temperature at a rate of 30 ml/min. Variables included volume at fi rst desire to void, volume at strong desire, volume at urgency, maximum cystometric capacity, bladder compliance, detrusor overactivity amplitude, maximum fl ow rate (Qmax), detrusor pressure at maximum fl ow rate (Pdet@Qmax), and postvoid residual volume. Involuntary detrusor contraction lower than 5 cmH 2 O were not considered as detrusor overactivity. The diagnosis of benign prostatic obstruction was done using 2 voiding pressure nomograms, Schafer's linear pressure urethral resistance relationship and the ICS nomogram, adapted from the Abrams/Griffi ths normogram. 19 After baseline evaluations were completed, participants were randomly allocated, using a computer-generated randomization list, to 1 of the 2 groups TTNS treatment group (GI) or sham group (GII). Patients were blinded to group assignment; that is, they were unaware of which group was the sham group until the end of the study.
A Duaplex 961 (Quark, São Paulo, Brazil) stimulator was used to perform TTNS. Transcutaneous tibial nerve stimulation or sham stimulation was administered over a 5-week period; each session lasted 30 minutes. Participants were treated twice weekly, resulting in 10 sessions. All treatment sessions were conducted by the same physiotherapist. Active TTNS treatment was delivered via 2 carbon rubber (HRQOL). 2 , 3 Our understanding of the pathophysiology of LUTS in patients with Parkinsonism is not entirely understood, 4 but several factors are postulated to contribute the high prevalence of LUTS among PD patients, including neurogenic bladder dysfunction and comorbid conditions such as prostate enlargement in men. 4 Several treatments are commonly used for LUTS in patients with PD, such as antimuscarinic drugs, botulinum toxin, or surgical intervention in selected cases, but these treatments are not always well tolerated. [5] [6] [7] [8] Conservative treatments such as bladder training, pelvic fl oor muscle training, and transcutaneous tibial nerve stimulation (TTNS) have been proposed as treatment options for LUTS in nonneurogenic population, but evidence of its effi cacy among patients with PD is sparse. [9] [10] [11] [12] [13] [14] [15] [16] The aim of this study was to evaluate the effect of TTNS in the treatment of LUTS in PD patients. Outcome measures included episodes of urgency and urge urinary incontinence, daytime voiding frequency, and nocturia episodes recorded on a 3-day bladder diary. We also measured LUTS, using the Overactive Bladder Version 8 (OAB-V8) questionnaire and HRQOL via the International Consultation on Incontinence Quality of Life Questionnaire Short Form (ICQ-SF). Urodynamic testing was used to measure maximum cystometric capacity, bladder wall compliance, maximum amplitude of detrusor activity, maximum fl ow rate (Qmax), detrusor pressure at maximum fl ow rate (Pdet @ Qmax), and postvoid residual volume.
■ Methods
A randomized controlled trial was conducted at the Urologic and Neurologic Clinic of Universidade Estadual de Campinas (Unicamp), Campinas, Brazil. The study was approved by the Institutional Ethical Committee (protocol number 783/2008), and written consent was given by the participants before the beginning of the treatment.
Inclusion criteria were (1) diagnosis of PD based on Unifi ed Parkinson's Disease Rating Scale (UPDRS) scores 17 ; (2) stable symptoms for 2 months (ie, no change in physical symptoms as tremor, bradykinesia, impaired posture, and balance and rigid muscles determined by patient report); and (3) cognitive ability to complete bladder log, LUTS, and HRQOL instruments. An additional inclusion criterion was presence of at least 2 of the following LUTS: urgency, urgency incontinence, daytime voiding frequency, nocturia (2 or more episodes were considered clinically relevant), or nocturnal enuresis. 18 Participants were excluded if they had urinary tract infection (confi rmed by laboratory test), had undergone to previous gynecologic surgery, pregnancy, severe cardiopulmonary disease, diabetes mellitus, bladder outlet obstruction with prostatic enlargement (diagnosis by urodynamic evaluation), or cancer.
Individuals using antimuscarinic, other medications for the treatment of LUTS, or medication to control PD were permitted to participate if they had been taking the Both questionnaires used in this study were translated and validated for the Portuguese language 1 , 21 , 22 and were fi lled out by the patients. The physiotherapist who collected data was allowed to assist subjects when completing this instrument when necessary.
Data Analyses
Statistical analyses were performed using Statistical Analysis System for Windows (SAS, Cary, North Carolina) software. Only patients who completed the study were analyzed. Due to the lack of normal distribution of the variables, a nonparametric test, Mann-Whitney U Test, was used to compare baseline measures before and after intervention between the 2 groups. To compare outcomes before and after the intervention in each group, a Wilcoxon test was used. A P value of ≤ .05 was considered statistically signifi cant for all tests.
■ Results
Between June 2011 and June 2012, 96 patients were identifi ed who fulfi lled inclusion criteria. Twenty-three agreed to participate in the research and 13 completed the study. Reasons for declining to participate or complete study procedures included inability to attend clinic for treatment twice weekly (n = 16), exclusion based on baseline evaluation (n = 31), not interested in TTNS as a treatment option (n = 17), unwillingness to undergo baseline evaluation procedures (n = 11), and lost to follow-up (n = 7). Figure 1 summarizes screened patients, subjects enrolled in the study, and participants who completed the study. Table 1 summarizes demographic characteristics of the active and sham treatment groups; no statistical differences were found between groups at baseline. In addition, no differences were electrodes. One electrode was placed below the left medial malleolus and the other one was located 5 cm cephalad to the distal electrode. Proper electrode location was confi rmed by the presence of great toe plantar fl exion during the delivery of a pulse width of 200 μ s at a frequency of 10 Hz with stimulus intensity at the patient's tolerance level. After the appropriate electrode site was confi rmed, the stimulation amplitude was reduced to a level just below the somatic sensory threshold. 13 , 20 Subjects allocated to the sham device (group II) were treated in a similar manner with the exception of active electrical stimulation. A pair of carbon rubber electrode was placed as described earlier for GI. The stimulation unit was turned on and the therapist increased the magnitude of the stimulation on the unit, but these manipulations did not deliver electrical simulation to the tibial nerve.
Instruments
The OAB-V8 questionnaire 21 was used to evaluate LUTS. This instrument is designed to rate how bothered patients are regarding 4 overactive bladder symptoms: urinary frequency, urgency, nocturia, and urgency incontinence. The subjects were considered to have a likely diagnosis of LUTS if their total score was more than 8. This questionnaire is commonly used to assess overactive bladder symptoms, but it has been useful to evaluate patients' self-perception of the symptoms caused by lower urinary tract dysfunction. 21 The ICIQ-SF 22 is a self-report questionnaire with 3 items that evaluate the frequency, severity, and impact of urinary incontinence and an 8-item scale assessing the possible causes or situations related to urinary incontinence. The fi nal ICIQ-SF score is the sum of the total scores, ranging from 0 to 21; higher scores indicate a more negative impact on HRQOL. 22 FIGURE 1. Flow diagram for study participants including potential patients excluded from participation and participants who withdrew before completing study procedures.
found when groups were compared based on adherence to biweekly treatment sessions (median for group I = 18.0 vs median for group II = 17.0; P = .56).
Following treatment, bladder diary assessment revealed that patients who underwent active TTNS treatment experienced a statistically signifi cant reduction in the number of urgency episodes over a 3-day period ( P < .04) ( Table 2 ) . Between-group analysis showed that no statistically signifi cant differences were found when the number of episodes of nocturia was compared between the sham group and the active treatment group ( P = .88). However, subjects allocated to active TTNS showed a reduction in the number of nocturia episodes (4.0 vs 2.0; P < .01) after 10 treatments, while those managed by the sham device showed no signifi cant differences ( Table 3 ) .
Signifi cant differences in OAB-V8 scores were found when patients allocated to the active TTNS group were compared at baseline and following treatment ( P < .03; Table 4 ). In contrast, no differences were found when patients allocated to the sham group were compared at baseline and following treatment ( P = .508). No differences were found when groups were compared following treatment ( P = .10). Similarly, analysis of ICIQ-SF scores revealed statistically signifi cant differences when subjects receiving active TTNS were compared ( P < .01), indicating increased HRQOL following treatment. In contrast, no differences were found when posttreatment scores were compared between the 2 groups ( P = .9279; Table 4 ).
Urodynamic testing revealed statistically signifi cant differences in the cystometric volume when subjects suppressing detrusor overactivity and improving bladder capacity. 13 , 20 In our study, TTNS reduced the number of episodes of urgency and nocturia on 3-day bladder log when compared to baseline values. Subjects allocated to TTNS also had signifi cant improvements in LUTS scores evaluated on the OAB-V8 and HRQOL based on ICIQ-SF scores. Urodynamic testing revealed signifi cant differences in the volume infused volume when strong desire to void and urgency were reported. TTNS also showed signifi cant differences on strong desire to void and urgency domains of urodynamic testing.
Participant Characteristics for Group I (Active TTNS) and Group II (Sham)
reported a strong desire to void ( P < .05) and infused volume when subjects reported urgency ( P < .01; Table 5 ). In contrast, patients undergoing sham treatment showed no differences in any urodynamic measure before and following treatment. No differences were found when groups were compared following the treatment.
■ Discussion
Transcutaneous tibial nerve stimulation is a noninvasive technique that has been reported to improve LUTS by Abbreviations: VFD, volume at fi rst desire to void; VSD, volume at strong desire; VU, volume at urgency; Max Cyst Cap, maximum cystometric capacity, bladder compliance measured as ml/cm H 2 O; Det Overactivity Ampl, detrusor overactivity amplitude; Qmax, maximum fl ow rate; Pdet Qmax, detrusor pressure at maximum fl ow rate; Postvoid Res, postvoid residual volume in ml; group I, active TTNS; group II, sham device. a Analysis reveals no difference between groups.
Previous studies in patients with idiopathic (nonneurogenic) overactive bladder dysfunction have reported encouraging results after a treatment program with TTNS, including signifi cant difference in voiding frequency, frequency of urgency urinary incontinence episodes, reductions in pad weight, and the number of nocturia episodes. 10 , 11 , 13 However, few studies have evaluated the effects of TTNS in patients with neurogenic bladder dysfunction such as that associated with PD. One previous nonrandomized controlled trial 20 conducted in patients with multiple sclerosis submitted to TTNS also found improvements of LUTS and urodynamic parameters.
While our fi ndings and those of previous studies of patients with neurogenic bladder dysfunction showed encouraging results after tibial nerve stimulation, the mechanisms underlying its effects on detrusor overactivity and related LUTS are not known. 11 , 20 Transcutaneous tibial nerve stimulation may inhibit detrusor overactivity by depolarizing somatic sacral and lumbar afferent fi bers. Afferent stimulation is postulated to provide central inhibition of preganglionic detrusor motor neurons through a direct route in the sacral cord, reestablishing the balance between inhibitory and excitatory impulses that control bladder function. 11 , 13 , 20 Additional research is needed to determine how PD impacts nervous control of the detrusor muscle, and how TTNS infl uences patients with PD and detrusor overactivity. 23 
Limitations
Ten out of 23 patients randomized into our study did not complete the study, primarily due to diffi culty attending twice weekly sessions. The dropout rate may have infl uenced study fi ndings. This signifi cant dropout rate also has possible clinical implications; further research should address the possibility of home-based TTNS with less frequent clinic visits. These considerations are especially important for patients with PD who have physical disabilities, rendering travel to an outpatient care center for multiple visits particularly diffi cult.
■ Conclusion
Findings from this study suggest that TTNS improves LUTS in PD. Additional research is needed to reproduce these fi ndings and to further explore potential barriers associated with the need for multiple clinic visits currently required to deliver TTNS.
